Abstract
In this issue of Blood, Kridel et al describe recurrent NOTCH1 mutations in mantle cell lymphoma (MCL) by next-generation sequencing of patient samples and cell lines. They further demonstrate a negative prognostic impact of NOTCH1 mutation in their cohort of patients and sensitivity of MCL cells to NOTCH1 inhibition in vitro, suggesting a novel role for NOTCH1 in this disease.
